- Home
- BOH vs NAMS Comparison
BOH vs NAMS Comparison
Compare BOH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOH
- NAMS
- Stock Information
- Founded
- BOH 1897
- NAMS 2019
- Country
- BOH United States
- NAMS Netherlands
- Employees
- BOH N/A
- NAMS N/A
- Industry
- BOH Major Banks
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BOH Finance
- NAMS Health Care
- Exchange
- BOH Nasdaq
- NAMS Nasdaq
- Market Cap
- BOH 2.8B
- NAMS 2.5B
- IPO Year
- BOH N/A
- NAMS N/A
- Fundamental
- Price
- BOH $65.62
- NAMS $23.60
- Analyst Decision
- BOH Hold
- NAMS Strong Buy
- Analyst Count
- BOH 5
- NAMS 9
- Target Price
- BOH $75.40
- NAMS $41.11
- AVG Volume (30 Days)
- BOH 379.8K
- NAMS 844.8K
- Earning Date
- BOH 07-28-2025
- NAMS 08-06-2025
- Dividend Yield
- BOH 4.24%
- NAMS N/A
- EPS Growth
- BOH N/A
- NAMS N/A
- EPS
- BOH 3.56
- NAMS N/A
- Revenue
- BOH $640,351,000.00
- NAMS $47,140,000.00
- Revenue This Year
- BOH $15.73
- NAMS N/A
- Revenue Next Year
- BOH $7.97
- NAMS N/A
- P/E Ratio
- BOH $18.54
- NAMS N/A
- Revenue Growth
- BOH N/A
- NAMS 586.97
- 52 Week Low
- BOH $57.45
- NAMS $14.06
- 52 Week High
- BOH $82.70
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BOH 38.44
- NAMS 67.01
- Support Level
- BOH $66.17
- NAMS $22.00
- Resistance Level
- BOH $68.72
- NAMS $24.82
- Average True Range (ATR)
- BOH 1.35
- NAMS 1.21
- MACD
- BOH -0.40
- NAMS 0.25
- Stochastic Oscillator
- BOH 6.85
- NAMS 77.98
About BOH Bank of Hawaii Corporation
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.